A drug being developed by New Haven’s Kleo Pharmaceuticals to treat the blood cancer multiple myeloma has been granted “orphan” status by the FDA.
The U.S. Food & Drug Administration awards “orphan” status to treatments for diseases affecting fewer than 200,000 people in the U.S., or for drugs that are not expected to recoup the costs of development and marketing.